Lifecore Biomedical, Inc. (LFCR)
Market Cap | 203.14M |
Revenue (ttm) | 103.27M |
Net Income (ttm) | -99.56M |
Shares Out | 30.55M |
EPS (ttm) | -3.32 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 13,441 |
Open | 6.63 |
Previous Close | 6.64 |
Day's Range | 6.60 - 6.74 |
52-Week Range | 4.13 - 11.46 |
Beta | 1.06 |
Analysts | Buy |
Price Target | 9.50 (+42.43%) |
Earnings Date | May 30, 2024 |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation... [Read more]
Full Company ProfileFinancial Performance
In 2023, LFCR's revenue was $103.27 million, a decrease of -7.19% compared to the previous year's $111.27 million. Losses were -$99.56 million, -14.70% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 42.43% from the latest price.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCR
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). Such investors are adv...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
NEW YORK , April 19, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Lifecore Biomedical ...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that, on April 15, 2024, the Company received a notification letter (the “Not...
LFCR INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
NEW YORK , April 12, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Lifecore Biomed...
ROSEN, A TOP RANKED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDC
NEW YORK--(BUSINESS WIRE)---- $LFCR #LFCR--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Lifecore Biome...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedi...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedic...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedic...
ONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedic...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedi...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Lifecore Biomedic...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) investors concerning the C...
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $LFCR #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (“Life...
The Law Offices of Frank R. Cruz Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) on behalf of investors concerning th...
Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update
CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedi...
Lifecore Class Action Lawsuit Investigation News – Potential to Make Claim, Recover Losses, Contact Johnson Fistel, LLP
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities laws by Lifecore Biomedical, Inc. (NASDAQ: LFCR). (“Lifecore” or the “Co...
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Lifecore Biomedical, Inc. (LFCR)
NEW YORK--(BUSINESS WIRE)---- $LFCR #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ:LFCR)....
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023
Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q
Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's Securities Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company...
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements
Top 5 Risk Off Stocks That May Explode This Quarter - AgriFORCE Growing Systems (NASDAQ:AGRI), Bit Brother (NASDAQ:BETS)
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
Lifecore Biomedical Provides Business Update
CHASKA, Minn., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provid...
Company Reaches Favorable Resolution Regarding Previously-Disclosed Investigation of Formerly-Held Subsidiary Yucatan Foods
CHASKA, Minn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that the U.S. Department of Justice (the “DOJ”) has declined to prosecute the ...